ECM
CLVS

Endurant Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Endurant Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-30,500
Closed -$1.39M – 88
2018
Q2 		$1.39M Sell
30,500
-2,600
-8% -$126K 0.6% 41
2018
Q1 		$1.75M Sell
33,100
-34,550
-51% -$2.02M 0.65% 39
2017
Q4 		$4.6M Buy
67,650
+10,900
+19% +$762K 1.41% 33
2017
Q3 		$4.68M Buy
56,750
+25,100
+79% +$1.99M 1.42% 25
2017
Q2 		$2.96M Sell
31,650
-200
-0.6% -$12.2K 0.84% 35
2017
Q1 		$2.03M Buy
31,850
+13,450
+73% +$818K 0.65% 44
2016
Q4 		$817K Buy
18,400
+10,100
+122% +$355K 0.34% 56
2016
Q3 		$299K Buy
+8,300
New +$178K 0.11% 91

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return